Sterling Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Sterling Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-37,833	Closed	-$637K	–	933
2018 Q2	$637K	Sell	37,833 -37	-0.1%	-$719	0.01%	728
2018 Q1	$867K	Buy	+37,870	New	+$842K	0.01%	665

Other funds holding CNCE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sterling Capital Management's CNCE Position: Q3 2018 in Review

Sterling Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2018, closing a stake of 37,833 shares — an estimated $637K sold.

Sterling Capital Management first reported a position in CNCE in Q1 2018 and held it in 2 quarters. The position peaked at $867K in Q1 2018. 111 funds tracked by Wall St. Rank hold CNCE as of Q3 2018.

Sterling Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Sterling Capital Management sold 37,833 Concert Pharmaceuticals, Inc. shares in Q3 2018, an estimated $637K.
Sterling Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2018 and held it in 2 quarters.
Sterling Capital Management's Concert Pharmaceuticals, Inc. position peaked at $867K in Q1 2018.
111 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2018.

Based on Sterling Capital Management's 13F filing for Q3 2018, filed 1 Nov 2018.